Physician profile
Jennifer Adele Demsar
NPI 1396218202
$1,502.66
in general payments reported to CMS, 2019-2025
13 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $67.88 · 2023: $238 · 2024: $426 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $502.51 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $347.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.47 | 2023-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.58 | 2021-2025 | Xifaxan |
| Pfizer INC. | $104.65 | 2021-2024 | |
| Novo Nordisk INC | $94.18 | 2021-2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.15 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.55 | 2021 | |
| Electromed, INC. | $28.32 | 2025 | Smartvest |
| Csl Behring | $23.81 | 2025 | Haegarda |
| Dexcom, INC. | $23.52 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $21.47 | 2025 | Repatha, Otezla |
| Sanofi Pasteur INC. | $14.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Demsar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.